Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle

被引:125
作者
Scheer, Frank A. J. L. [1 ,2 ]
Shea, Steven A. [1 ,2 ,3 ]
机构
[1] Brigham & Womens Hosp, Div Sleep Med, Med Chronobiol Program, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA
基金
美国国家卫生研究院;
关键词
MYOCARDIAL-INFARCTION; FIBRINOLYTIC-ACTIVITY; RHYTHM; GENE; FLUCTUATIONS; OSCILLATION; COMPONENTS; EXERCISE; PROMOTER; BLOOD;
D O I
10.1182/blood-2013-07-517060
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serious adverse cardiovascular events peak in the morning, possibly related to increased thrombosis in critical vessels. Plasminogen activator inhibitor-1 (PAI-1), which inhibits fibrinolysis, is a key circulating prothrombotic factor that rises in the morning in humans. We tested whether this morning peak in PAI-1 is caused by the internal circadian system or by behaviors that typically occur in the morning, such as altered posture and physical activity. Twelve healthy adults underwent a 2-week protocol that enabled the distinction of endogenous circadian effects from behavioral and environmental effects. The results demonstrated a robust circadian rhythm in circulating PAI-1 with a peak corresponding to similar to 6:30 AM. This rhythm in PAI-1 was 8-times larger than changes in PAI-1 induced by standardized behavioral stressors, including head-up tilt and 15-minute cycle exercise. If this large endogenous morning peak in PAI-1 persists in vulnerable individuals, it could help explain the morning peak in adverse cardiovascular events.
引用
收藏
页码:590 / 593
页数:4
相关论文
共 50 条
  • [21] Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene
    Panahloo, A
    Mohammad-Ali, V
    Gray, RP
    Humphries, SE
    Yudkin, JS
    ATHEROSCLEROSIS, 2003, 168 (02) : 297 - 304
  • [22] Elevated expression of plasminogen activator inhibitor (PAI-1/SERPINE1) is independent from rs1799889 genotypes in arthrofibrosis
    Bayram, Banu
    Owen, Aaron R.
    Dudakovic, Amel
    Bettencourt, Jacob W.
    Limberg, Afton K.
    Morrey, Mark E.
    Sanchez-Sotelo, Joaquin
    Berry, Daniel J.
    Kocher, Jean-Pierre A.
    van Wijnen, Andre J.
    Abdel, Matthew P.
    META GENE, 2021, 28
  • [23] Circadian Variation of Plasminogen-Activator Inhibitor-1 Levels in Children with Meningococcal Sepsis
    Boeddha, Navin P.
    Driessen, Gertjan J.
    Cnossen, Marjon H.
    Hazelzet, Jan A.
    Emonts, Marieke
    PLOS ONE, 2016, 11 (11):
  • [24] Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis A meta-analysis
    Bae, S-C
    Lee, Y. H.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2020, 79 (03): : 312 - 318
  • [25] Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke
    Sabino, Adriano de Paula
    Ribeiro, Daniel Dias
    Domingueti, Caroline Pereira
    dos Santos, Mariana Silva
    Gadelha, Telma
    SantAna Dusse, Luci Maria
    Carvalho, Maria das Gracas
    Fernandes, Ana Paula
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (08) : 5355 - 5360
  • [26] Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters - The HIFMECH study
    Morange, P. E.
    Saut, N.
    Alessi, M. C.
    Yudkin, J. S.
    Margaglione, M.
    Di Minno, G.
    Hamsten, A.
    Humphries, S. E.
    Tregouet, D. A.
    Juhan-Vague, I.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (10) : 2250 - 2257
  • [27] Stimulated in vivo synthesis of plasminogen activator inhibitor-1 in human adipose tissue
    Ekstrom, Mattias
    Liska, Jan
    Eriksson, Per
    Sverremark-Ekstrom, Eva
    Tornvall, Per
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (03) : 485 - 492
  • [28] The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer
    Yildirim, Malik Ejder
    Karakus, Savas
    Kurtulgan, Hande Kucuk
    Kilicgun, Hasan
    Ersan, Serpil
    Bakir, Sevtap
    BIOCHEMICAL GENETICS, 2017, 55 (04) : 314 - 321
  • [29] The plasminogen activator inhibitor-1 (PAI-1) gene-844 A/G and-675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome
    Sun Lin
    Zhang Huiya
    Liu Bo
    Wei Wei
    Guan Yongmei
    ENDOCRINE, 2009, 36 (03) : 503 - 509
  • [30] The anti-fibrinolytic SERPIN, plasminogen activator inhibitor 1 (PAI-1), is targeted to and released from catecholamine storage vesicles
    Jiang, Qijiao
    Gingles, Neill A.
    Olivier, Marc A.
    Miles, Lindsey A.
    Parmer, Robert J.
    BLOOD, 2011, 117 (26) : 7155 - 7163